source
- New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budgetThe FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…
- Congress pushes back on White House plan to place political appointees on NIH grant reviewsMembers of Congress have voiced strong opposition after a leak revealed a White House proposal to create a commission of political appointees that would review every NIH grant. The idea reportedly…